Pfizer's $100 billion offer to acquire British rival AstraZeneca is an effort to achieve an "efficient" tax structure, the company said.
Stocks rose on Monday, bouncing back after the prior session's drop, amid increased deal activity.
CNBC's Eamon Javers takes a close look at Pfizer's $100 billion bid for AstraZeneca. The deal would elevate Pfizer's cancer drug pipeline while giving them enormous tax savings.
Damien Conover, Morningstar analyst, thinks the Pfizer bid for AstraZeneca will go through. CNBC's Meg Tirrell provides perspective.
The euro rose to a two-week high against the dollar on Monday, supported by expectations inflation in the euro zone will tick up.
CNBC's Eamon Javers takes a close look at Pfizer's $100 billion bid for AstraZeneca.
With stocks buoyed by a flurry of dealmaking on Monday, Blackstone CEO Steve Schwarzman says absolute valuations are "on the higher side."
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Investors are unwinding leverage somewhat, yet most remain committed to the stock market amid talk of a new rotation.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
Some of the names on the move ahead of the open.
Bayer CEO Marijn Dekkers told CNBC he did not feel a need to make acquisitions on Monday.
U.S. stock index futures pointed to a higher open on Monday, after Pfizer confirmed it had made a second bid for AstraZeneca.
Shares in UK pharma group soar 15 percent on news that potential $100 billion-plus merger seems to have moved a step closer.
Pfizer has renewed its interest in a takeover of UK rival AstraZeneca, in what would be one of the global drugs industry’s largest ever deals.
Alex Tarrant, M&A reporter at Dealreporter, discusses the implications of a potential deal between Pfizer and AstraZeneca.
These 10 stocks had been out of favor. But now, they're kind of ‘in crowd.’
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
European shares closed higher on Tuesday, starting a shortened trading week on a positive note.